Related Videos
ESMO26: Toni Choueiri, MD, on KEYNOTE-564
Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.
ESMO26: Toni Choueiri, MD on LITESPARK-012
Surprising results in first triplet combination study in advanced kidney cancer presented by Toni Choueiri, MD, at #ESMO26. Dr. Choueiri says even though the combination did not improve efficacy, the findings are important for informing future studies.
ASCO26: Toni Choueiri, MD, KEYNOTE-654
Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ...
2026 ASCO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates
Kidney Cancer Highlights from ASCO 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2025.
ARC-20 Study Presented by Toni Choueiri, MD.
Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.
Checkmate 214 Presented by Toni Choueiri, MD.
Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.
Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan
Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.
Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101
Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.
